#Comment🚨
Swanton&Co @charlesswanton.bsky.social highlight the histories of EGFR, HER2, CDK4/6 and RAS, and discusses how sustained investment in discovery science continues to generate clinical benefit through new drugs, indications and treatment combinations.
📖⬇️

dlvr.itThe long return on discovery science in cancer therapeutics - Nature Reviews CancerMany advances in cancer treatment depend on discoveries made decades earlier. In this Comment, Murphy et al. discuss the histories of EGFR, HER2, CDK4/6 and RAS, highlighting how long translation can take and how clinical benefit can continue to accumulate as more effective drugs are developed, used in earlier disease settings and combined with existing treatments.